Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 22, 2022

SELL
$22.29 - $35.04 $180,994 - $284,524
-8,120 Reduced 44.97%
9,937 $263,000
Q1 2022

May 16, 2022

SELL
$24.62 - $34.31 $24,866 - $34,653
-1,010 Reduced 5.3%
18,057 $599,000
Q4 2021

Feb 14, 2022

BUY
$30.19 - $40.28 $295,862 - $394,744
9,800 Added 105.75%
19,067 $623,000
Q3 2021

Nov 15, 2021

SELL
$29.09 - $45.68 $174 - $274
-6 Reduced 0.06%
9,267 $388,000
Q2 2021

Aug 16, 2021

SELL
$32.46 - $40.48 $34,699 - $43,273
-1,069 Reduced 10.34%
9,273 $360,000
Q1 2021

May 18, 2021

SELL
$33.61 - $49.95 $70,581 - $104,895
-2,100 Reduced 16.88%
10,342 $353,000
Q4 2020

Feb 17, 2021

SELL
$26.52 - $49.35 $36,332 - $67,609
-1,370 Reduced 9.92%
12,442 $564,000
Q3 2020

Nov 19, 2020

BUY
$27.01 - $40.26 $70,766 - $105,481
2,620 Added 23.41%
13,812 $380,000
Q2 2020

Aug 14, 2020

BUY
$27.75 - $43.44 $1,387 - $2,172
50 Added 0.45%
11,192 $412,000
Q1 2020

May 13, 2020

SELL
$21.5 - $54.2 $6,235 - $15,718
-290 Reduced 2.54%
11,142 $361,000
Q4 2019

Feb 18, 2020

BUY
$34.54 - $44.87 $36,957 - $48,010
1,070 Added 10.33%
11,432 $468,000
Q3 2019

Nov 15, 2019

BUY
$31.84 - $50.88 $88,196 - $140,937
2,770 Added 36.49%
10,362 $369,000
Q2 2019

Aug 12, 2019

BUY
$42.0 - $59.29 $88,200 - $124,509
2,100 Added 38.24%
7,592 $390,000
Q1 2019

May 16, 2019

BUY
$40.82 - $62.45 $17,634 - $26,978
432 Added 8.54%
5,492 $315,000
Q4 2018

Feb 15, 2019

BUY
$39.11 - $75.15 $55,536 - $106,713
1,420 Added 39.01%
5,060 $212,000
Q3 2018

Nov 14, 2018

BUY
$65.0 - $82.15 $24,050 - $30,395
370 Added 11.31%
3,640 $275,000
Q2 2018

Aug 13, 2018

BUY
$27.2 - $74.35 $88,944 - $243,124
3,270 New
3,270 $235,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $413M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Iht Wealth Management, LLC Portfolio

Follow Iht Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Iht Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Iht Wealth Management, LLC with notifications on news.